Can I buy cosyntropin without a prescription in the US?

No. Cosyntropin is an FDA-approved prescription drug and cannot be legally purchased over the counter or without a physician's order. It must be obtained through licensed pharmacies, hospitals, or clinics with a valid prescription from a healthcare provider.

Is it legal to order cosyntropin from international suppliers?

No. Importing cosyntropin from international sources without proper authorization is illegal under US federal law. The FDA and DEA enforce against unauthorized importation of approved drugs. Cosyntropin must be sourced through licensed US pharmaceutical distributors.

What is the difference between FDA-approved cosyntropin and 'research-grade' versions?

There is no legal 'research-grade' cosyntropin for human use in the US. Because it is an approved drug, all cosyntropin is regulated as a pharmaceutical. Any product labeled 'research-only' or sourced outside licensed channels is illegal. Legitimate cosyntropin comes with proper pharmaceutical labeling and documentation.

Can cosyntropin be used for anything other than diagnostic testing?

Cosyntropin's FDA approval is specifically for diagnostic use in ACTH stimulation tests. It is not approved or legal to use as a treatment for any condition. Its clinical utility is limited to assessing adrenal gland function, not modifying it.

Why is cosyntropin not approved in Canada or Europe?

Regulatory approval varies by jurisdiction. Cosyntropin may not meet the approval thresholds set by Health Canada or the EMA, or those regions may rely on alternative diagnostic methods. FDA approval in the US does not automatically translate to approval elsewhere. Different regulatory bodies have different clinical standards and approval processes.

Cosyntropin Legal Status in the US: FDA Approval & Regulations

Cosyntropin is FDA-approved in the United States and fully legal for medical use. Sold under the brand name Cortrosyn, it is classified as an approved pharmaceutical diagnostic agent—not a treatment, but a clinical tool used in ACTH stimulation tests to evaluate adrenal gland function. The compound has been legally available for decades and is the standard reagent for diagnosing adrenal insufficiency and monitoring patients on long-term corticosteroid therapy. Because cosyntropin is an approved drug, it is tightly regulated, manufactured to pharmaceutical standards, and only available by prescription through licensed healthcare providers.

What Is Cosyntropin?

Cosyntropin is a synthetic peptide that mimics adrenocorticotropic hormone (ACTH), a natural hormone that signals the adrenal glands to produce cortisol. Unlike many peptides discussed in the research space, cosyntropin is not experimental—it is an established diagnostic pharmaceutical with a clear regulatory pathway and decades of clinical use.

The key distinction: cosyntropin is a diagnostic tool, not a treatment. It is used in the ACTH stimulation test, one of the most frequently performed endocrine diagnostic tests in the United States, to assess whether a patient's adrenal glands respond normally to hormonal signals.

FDA Approval Status

Cosyntropin holds full FDA approval in the United States. The FDA classifies it as an approved drug product, regulated under standard pharmaceutical oversight. The brand name Cortrosyn is the most widely recognized formulation, though cosyntropin is available under other brand names and as a generic compound through licensed manufacturers.

Because cosyntropin is FDA-approved, it is:

Legal to manufacture and distribute in the United States
Legal to prescribe by licensed physicians
Legal to administer in clinical and hospital settings
Covered by insurance when medically indicated
Subject to pharmaceutical manufacturing standards (cGMP compliance)
Tracked in the FDA's approved drug database

Regulatory Classification

Cosyntropin is classified as a prescription drug in the United States. It cannot be legally purchased over the counter or without a physician's order. The compound falls under FDA drug approval regulations because it is a biologic (a synthetic peptide) with clinical utility, and its manufacture, distribution, and use are governed by the Code of Federal Regulations (CFR) Title 21.

As an approved diagnostic agent, cosyntropin is not subject to the same ongoing clinical trial requirements that investigational compounds face. The FDA has already established its safety profile and clinical efficacy through prior approval processes, so it can be legally dispensed and used without additional trial enrollment.

Clinical Use and Standards

The standard ACTH stimulation test protocol using cosyntropin is well-defined in clinical practice:

Standard dose: 250 mcg administered intravenously or intramuscularly
Measurement timing: Blood cortisol levels are measured at baseline, 30 minutes, and 60 minutes post-injection
Clinical purpose: To diagnose adrenal insufficiency or assess adrenal reserve in patients on long-term corticosteroid therapy

According to data in the PeptideTrace clinical trial database, cosyntropin appears in 38 registered clinical trials, most of which focus on refining diagnostic thresholds rather than investigating the compound itself. This reflects cosyntropin's mature status as an established diagnostic tool.

A lower-dose variant (1 mcg instead of 250 mcg) has been studied in research settings as potentially more sensitive for detecting partial adrenal dysfunction, but the 250 mcg standard remains the established clinical practice and the basis for FDA approval.

Prescription and Access

In the United States, cosyntropin can only be legally obtained through:

A licensed physician's prescription
Licensed pharmaceutical distributors
Hospital/clinic procurement systems
Specialty pharmacies that handle injectable medications

Cosyntropin is typically administered in clinical settings (hospitals, diagnostic imaging centers, endocrinology offices) where trained medical professionals can perform the test and interpret results. Some patients with chronic adrenal insufficiency may have cosyntropin prescribed for at-home diagnostic monitoring, but this requires direct physician oversight.

Manufacturing and Quality Standards

Because cosyntropin is FDA-approved, all manufacturers must comply with current Good Manufacturing Practice (cGMP) regulations. This means:

Raw materials are tested for purity and identity
Manufacturing processes are validated and controlled
Each batch is tested for sterility, potency, and safety
Records are maintained and subject to FDA inspection
Adverse events are reported to the FDA through pharmacovigilance systems

This regulatory oversight ensures that approved cosyntropin products meet consistent standards for potency, purity, and safety—a critical requirement for a diagnostic agent that influences clinical decision-making.

What About Grey-Market or Research-Grade Cosyntropin?

In the United States, it is illegal to manufacture, distribute, or sell cosyntropin outside of the FDA-approved pharmaceutical supply chain. Because cosyntropin is an approved drug (not a research compound), there is no legal "research-grade" version for human use.

Any cosyntropin sold outside of licensed pharmaceutical channels—whether labeled as "research-only," "not for human consumption," or sourced from international suppliers without FDA authorization—violates federal law. The FDA and DEA actively monitor and enforce against unauthorized distribution of approved drugs.

Patients or healthcare providers seeking cosyntropin should only obtain it through:

Licensed pharmacies with a valid prescription
Hospital/clinic supply systems
Specialty pharmaceutical distributors registered with the DEA

International Context

Cosyntropin's legal status varies internationally. In the United States, it is FDA-approved and fully legal. However, it is important to note that cosyntropin is not authorised by the European Medicines Agency (EMA) and not approved by Health Canada. This means European and Canadian physicians may use alternative diagnostic methods or must access cosyntropin through special authorization pathways if available.

This regulatory fragmentation is common in diagnostics: a compound can be standard-of-care in one jurisdiction and unavailable in another due to different approval processes and clinical standards.

Enforcement and Compliance

The FDA actively monitors the supply chain for cosyntropin. Unauthorized sales, counterfeit products, or distribution violations are investigated and prosecuted. Healthcare facilities that use cosyntropin must:

Maintain proper licensing and accreditation
Keep records of cosyntropin use and test results
Report adverse events to the FDA
Use only FDA-approved sources

Patients should be aware that legitimate cosyntropin will always come with proper pharmaceutical packaging, labeling, and documentation from a licensed provider.

What Consumers Should Know

Cosyntropin is not a treatment or medication you can self-administer for a health condition. It is exclusively a diagnostic tool that must be ordered and interpreted by a qualified healthcare provider. If a healthcare provider recommends an ACTH stimulation test, the cosyntropin used in that test is automatically FDA-approved and legally sourced through their institution.

If you are seeking diagnostic evaluation for suspected adrenal insufficiency, work with an endocrinologist or internal medicine specialist who can order the appropriate tests—they will access cosyntropin through legal pharmaceutical channels.

Related Peptide Compounds and Diagnostics

Cosyntropin's diagnostic role in assessing the hypothalamic-pituitary-adrenal (HPA) axis is unique, but it is often part of broader endocrine evaluation. Other diagnostic and therapeutic peptides in the regulatory landscape include GHRP-2 (investigational growth hormone secretagogue) and Sermorelin (approved for growth hormone evaluation), though these serve different clinical purposes.

For patients with confirmed adrenal insufficiency who need cortisol replacement, treatment relies on glucocorticoid medications (like prednisone or hydrocortisone), not on cosyntropin itself. Cosyntropin's role ends once the diagnostic test is complete.

Regulatory Summary

Cosyntropin holds a unique position in the peptide landscape: it is fully approved, legally available, tightly regulated, and universally recognized as the standard diagnostic agent for adrenal assessment. Unlike investigational peptides or research compounds, there is no ambiguity about its legal status in the United States—it is an approved pharmaceutical, available by prescription only, and manufactured to the highest standards. This regulatory clarity and clinical maturity make cosyntropin one of the most trusted diagnostic tools in endocrinology.

Cosyntropin Legal Status in the United States